Anti-infective skin replacement therapy - Stratatech

Drug Profile

Anti-infective skin replacement therapy - Stratatech

Alternative Names: ExpressGraft™ - Anti-microbial; ExpressGraft™ - C9T1; NIKSC9T1

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer National Institute of Diabetes and Digestive and Kidney Diseases; Stratatech
  • Class Cell therapies
  • Mechanism of Action Cathecilidin expression stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Diabetic foot ulcer; Varicose ulcer

Most Recent Events

  • 01 Feb 2018 Phase-I clinical trials in Diabetic foot ulcer in USA (Topical) (NCT02657876)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (Topical, Patch)
  • 17 Jan 2017 Stratatech plans a phase-I clinical trials in Diabetic foot ulcer in USA (Topical) (NCT02657876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top